ITOS vs. AUPH, SNDX, COLL, ALVR, SYRE, ELVN, GYRE, ADPT, NTLA, and ZYME
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), AlloVir (ALVR), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Gyre Therapeutics (GYRE), Adaptive Biotechnologies (ADPT), Intellia Therapeutics (NTLA), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs.
iTeos Therapeutics (NASDAQ:ITOS) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
iTeos Therapeutics currently has a consensus target price of $22.25, indicating a potential upside of 189.71%. Aurinia Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 25.00%. Given iTeos Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe iTeos Therapeutics is more favorable than Aurinia Pharmaceuticals.
iTeos Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat iTeos Therapeutics' return on equity.
iTeos Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
In the previous week, iTeos Therapeutics and iTeos Therapeutics both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.94 beat iTeos Therapeutics' score of 0.93 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
Aurinia Pharmaceuticals received 531 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 79.25% of users gave iTeos Therapeutics an outperform vote while only 73.27% of users gave Aurinia Pharmaceuticals an outperform vote.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aurinia Pharmaceuticals has higher revenue and earnings than iTeos Therapeutics. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
iTeos Therapeutics beats Aurinia Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 1/30/2025 by MarketBeat.com Staff
